“Cancer 2015”: A Prospective, Population-Based Cancer Cohort—Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic

Journal of Personalized Medicine

John P. Parisot¹¹  Heather Thorne¹¹  Andrew Fellowes⁷  Ken Doig¹¹  Mark Lucas²  John J. McNeil²  Brett Doble⁸  Alexander Dobrovic¹²  Thomas John⁵  Paul A. James¹  Lara Lipton³  David Ashley⁶  Theresa Hayes^9,11  Paul McMurrick^10,11  Gary Richardson^4,11  Paula Lorgelly⁸  Stephen B. Fox¹¹  David M. Thomas¹¹ 

[1] Division of Cancer Medicine, Peter MacCallum Cancer Centre, East Melbourne VIC 3002, Australia; E-Mail:;Department of Epidemiology and Preventative Medicine, Alfred Centre, Monash University, Prahran VIC 3181, Australia; E-Mails:;Department of Medical Oncology, The Royal Melbourne Hospital, Melbourne Health, Parkville VIC 3010, Australia; E-Mail:;Haematology and Oncology, Cabrini Institute, Cabrini Health, Malvern VIC 3144, Australia; E-Mail:;School of Cancer Medicine, La Trobe University, Bundoora VIC 3084, Australia;The Andrew Love Cancer Centre, Geelong Hospital, Barwon Health, Geelong VIC 3220, Australia; E-Mail:;Department of Pathology, Peter MacCallum Cancer Centre, East Melbourne VIC 3002, Australia; E-Mail:;Centre for Health Economics, Monash University, Clayton VIC 3800, Australia; E-Mails:;Warrnambool Hospital, SouthWest Healthcare, Warrnambool VIC 3280, Australia; E-Mail:;Department of Surgery, Cabrini Institute, Cabrini Health, Malvern VIC 3144, Australia; E-Mail:;Division of Cancer Research, Peter MacCallum Cancer Centre, 7 St Andrews Place, East Melbourne VIC 3002, Australia; E-Mails:;Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville VIC 3010, Australia

关键词: cancer genomics cohort;    next-Gen sequencing;    precision medicine;    health economics;   

DOI  :  10.3390/jpm5040354

来源: mdpi

【 摘 要 】

“Cancer 2015” is a longitudinal and prospective cohort. It is a phased study whose aim was to pilot recruiting 1000 patients during phase 1 to establish the feasibility of providing a population-based genomics cohort. Newly diagnosed adult patients with solid cancers, with residual tumour material for molecular genomics testing, were recruited into the cohort for the collection of a dataset containing clinical, molecular pathology, health resource use and outcomes data. 1685 patients have been recruited over almost 3 years from five hospitals. Thirty-two percent are aged between 61–70 years old, with a median age of 63 years. Diagnostic tumour samples were obtained for 90% of these patients for multiple parallel sequencing. Patients identified with somatic mutations of potentially “actionable” variants represented almost 10% of those tumours sequenced, while 42% of the cohort had no mutations identified. These genomic data were annotated with information such as cancer site, stage, morphology, treatment and patient outcomes and health resource use and cost. This cohort has delivered its main objective of establishing an upscalable genomics cohort within a clinical setting and in phase 2 aims to develop a protocol for how genomics testing can be used in real-time clinical decision-making, providing evidence on the value of precision medicine to clinical practice.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.